1Sachse C, Brockmoller J, Bauer S, et al. CytochromeP4502D6'variants in a caucasian population: allele flrequencies and phenotypic consequences [J]. Am Jhum Genet, 1997, 60(5):284--295.
2Christensen PM , Gotzsche PC , Brosen K , et al . The sparteine/debrisoquine ( CYP2D6 ) oxidation polymorphism and the risk of Parkinson's disease: ameta analysis [J]. Pharmacogenetics, 1998, 8 (8) : 473--479.
4Tan EK, Khajavi M, Thornby J, et al. Variability and validity of polymorphism association studies in parkinsons disease [J]. Neurology, 2000, 55 ( 9 ) : 533--538.
5Hsiao SL,Edward L. 5-Flanking region polymorphism of the neuronalnitric oxidesynthase gene with Parkinson's disease in Taiwan [J]. Journal of the NeurologicaScience, 2002, 194(1): 11--13.
6Lin J J, Yueh KC, Chang DC, et al. The homnozygote 10-copy genotype of variable numhert and emrepeat dopamine transporter, genemayconfer protection against Parkinsons disease formale, but not to female patients[J]. J Neurol Sci, 2003, 209 (2) :87--92.
7Bandmann O , Vaughhan J , Hohnans P , et al .Association of slow acetylator genotype for N-aeety transferase 2 with familial Parkinson's disease [J]. Ancet, 1997, 350(10):1136--1139.
8Agundez JAG, Jimenez FJ, Vengo A, et al. Slowallotypic variants of the NAT2 gene and susceptibility to early-onset Parkinsons disease [J].Neurology, 1998, 51 (7):1587--1592.
9Liu Y, Fallon L, Lashuel HA, et al. The UCH--1 geneencodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility [J]. Cell, 2002, 111(2):209-- 218.
